PD-L1 Expression Is Significantly Associated with Tumor Mutation Burden and Microsatellite Instability Score

Use of an Integrated Pan-Cancer Oncology Enrichment Next-Generation Sequencing Assay to Measure Tumour Mutational Burden and Detect Clinically Actionable Variants

(2020) Valerie Pestinger et al.   Molecular Diagnosis & Therapy

Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma

(2020) Matthew Kyle Labriola et al.   Journal for ImmunoTherapy of Cancer

Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence

(2020) Raju K. Vaddepally et al.   Cancers

Evaluation of a Hybrid Capture–Based Pan-Cancer Panel for Analysis of Treatment Stratifying Oncogenic Aberrations and Processes

(2020) Leonie I. Kroeze et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Analysis of tumor mutational burden: correlation of five large gene panels with whole exome sequencing

(2020) Carina Heydt et al.   Scientific Reports

A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases

(2020) Richard S. P. Huang et al.   MODERN PATHOLOGY

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

(2019) Robert M. Samstein et al.   NATURE GENETICS

PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer

(2019) Yanhui Chen et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Association Between Tumor Mutation Burden (TMB) and Outcomes of Cancer Patients Treated With PD-1/PD-L1 Inhibitions: A Meta-Analysis

(2019) Jiaxin Zhu et al.   Frontiers in Pharmacology

Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study

(2019) Andrea Forschner et al.   Journal for ImmunoTherapy of Cancer

Tumor mutational burden quantification from targeted gene panels: major advancements and challenges

(2019) Laura Fancello et al.   Journal for ImmunoTherapy of Cancer

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

(2019) Angel Garcia-Diaz et al.   Cell Reports

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases

(2018) E E Vokes et al.   ANNALS OF ONCOLOGY

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

(2018) Matthew D. Hellmann et al.   CANCER CELL

Comprehensive molecular profiling of intra- and extrahepatic cholangiocarcinomas: potential targets for intervention

(2018) Maeve A Lowery et al.   CLINICAL CANCER RESEARCH

Accurate Pan-Cancer Molecular Diagnosis of Microsatellite Instability by Single-Molecule Molecular Inversion Probe Capture and High-Throughput Sequencing

(2018) Adam Waalkes et al.   CLINICAL CHEMISTRY

Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers

(2018) Mohamed E. Salem et al.   MOLECULAR CANCER RESEARCH

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

(2018) Matthew D. Hellmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Size Matters: Dissecting Key Parameters for Panel-Based Tumor Mutational Burden (TMB) Analysis

(2018) Ivo Buchhalter et al.   INTERNATIONAL JOURNAL OF CANCER

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

(2018) David R. Gandara et al.   NATURE MEDICINE

Effectiveness and safety of immune checkpoint inhibitors: A retrospective study in Taiwan

(2018) Jason C. Hsu et al.   PLoS One

Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic

(2018) T A Chan et al.   ANNALS OF ONCOLOGY

Molecular and Computational Methods for the Detection of Microsatellite Instability in Cancer

(2018) Laura G. Baudrin et al.   Frontiers in Oncology

Landscape of genomic alterations (GA) and tumor mutational burden (TMB) in different metastatic melanoma (MM) subtypes.

(2017) Douglas Buckner Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project

(2017) Fred R. Hirsch et al.   Journal of Thoracic Oncology

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

(2017) Achim Rittmeyer et al.   LANCET

Assessment of Concordance between 22C3 and SP142 Immunohistochemistry Assays regarding PD-L1 Expression in Non-Small Cell Lung Cancer

(2017) Haipeng Xu et al.   Scientific Reports

Systemic and Adjuvant Therapies for Intrahepatic Cholangiocarcinoma

(2017) Yun Shin Chun et al.   Cancer Control

A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer

(2017) David L. Rimm et al.   JAMA Oncology

GenVisR: Genomic Visualizations in R

(2016) Zachary L. Skidmore et al.   BIOINFORMATICS

Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice

(2016) Apurva Jain et al.   CURRENT TREATMENT OPTIONS IN ONCOLOGY

Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade

(2016) D. B. Johnson et al.   Cancer Immunology Research

Novel technologies and emerging biomarkers for personalized cancer immunotherapy

(2016) Jianda Yuan et al.   Journal for ImmunoTherapy of Cancer

Epstein-Barr virus infection serves as an independent predictor of survival in patients with lymphoepithelioma-like gastric carcinoma

(2015) Byung-Hoon Min et al.   Gastric Cancer

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

(2015) S. P. Patel et al.   MOLECULAR CANCER THERAPEUTICS

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

(2015) N. A. Rizvi et al.   SCIENCE

Performance comparison of four exome capture systems for deep sequencing

(2014) Chandra Sekhar Chilamakuri et al.   BMC GENOMICS

Microsatellite Instability Detection by Next Generation Sequencing

(2014) S. J. Salipante et al.   CLINICAL CHEMISTRY

Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing

(2014) Mahesh Yadav et al.   NATURE

Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells

(2013) S. Spranger et al.   Science Translational Medicine

Reflex Immunohistochemistry and Microsatellite Instability Testing of Colorectal Tumors for Lynch Syndrome Among US Cancer Programs and Follow-Up of Abnormal Results

(2012) Laura C. Beamer et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Epitope Landscape in Breast and Colorectal Cancer

(2008) N. H. Segal et al.   CANCER RESEARCH

Differences and evolution of the methods for the assessment of microsatellite instability

(2008) L Laghi et al.   ONCOGENE